Immunotherapy for hepatocellular carcinoma: Current status and future perspectives DOI Creative Commons
Deepa S. Mandlik, Satish K. Mandlik,

Heena B Choudhary

et al.

World Journal of Gastroenterology, Journal Year: 2023, Volume and Issue: 29(6), P. 1054 - 1075

Published: Feb. 10, 2023

Hepatocellular carcinoma (HCC) is one of the world's deadliest and fastest-growing tumors, with a poor prognosis. HCC develops in context chronic liver disease. Curative resection, surgery (liver transplantation), trans-arterial chemoembolization, radioembolization, radiofrequency ablation chemotherapy are common treatment options for HCC, however, they will only assist limited percentage patients. Current treatments advanced ineffective aggravate underlying condition. Despite promising preclinical early-phase clinical trials some drugs, existing systemic therapeutic methods tumor stages remain limited, underlining an unmet need. In current years, cancer immunotherapy has made significant progress, opening up new HCC. on other hand, variety causes can affects body's immune system via mechanisms. With speedy advancement synthetic biology genetic engineering, range innovative immunotherapies, such as checkpoint inhibitors [anti-programmed cell death-1 (PD-1), anti-cytotoxic T lymphocyte antigen-4, anti-PD ligand 1 death antibodies], vaccines, engineered cytokines, adoptive therapy have all been used this review, we summarize present landscape immunotherapies critically discuss recent trial outcomes, address future perspectives field cancer.

Language: Английский

Immunotherapies for hepatocellular carcinoma DOI
Josep M. Llovet, Florian Castet, Mathias Heikenwälder

et al.

Nature Reviews Clinical Oncology, Journal Year: 2021, Volume and Issue: 19(3), P. 151 - 172

Published: Nov. 11, 2021

Language: Английский

Citations

1170
Evolving therapeutic landscape of advanced hepatocellular carcinoma DOI
Chen Yang, Hailin Zhang,

Linmeng Zhang

et al.

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2022, Volume and Issue: 20(4), P. 203 - 222

Published: Nov. 11, 2022

Language: Английский

Citations

429
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma DOI
Andrew X. Zhu, Alexander R. Abbas, Marina Ruiz de Galarreta

et al.

Nature Medicine, Journal Year: 2022, Volume and Issue: 28(8), P. 1599 - 1611

Published: June 23, 2022

Language: Английский

Citations

363
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma DOI
Josep M. Llovet, Roser Pinyol, Robin Kate Kelley

et al.

Nature Cancer, Journal Year: 2022, Volume and Issue: 3(4), P. 386 - 401

Published: April 28, 2022

Language: Английский

Citations

277
Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors DOI Creative Commons
Daniel Q. Huang, Philippe Mathurin, Helena Cortez‐Pinto

et al.

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2022, Volume and Issue: 20(1), P. 37 - 49

Published: Oct. 18, 2022

Heavy alcohol consumption is a major cause of morbidity and mortality. Globally, per-capita rose from 5.5 litres in 2005 to 6.4 2016 projected increase further 7.6 2030. In 2019, an estimated 25% global cirrhosis deaths were associated with alcohol. The age-standardized death rate (ASDR) alcohol-associated was 4.5 per 100,000 population, the highest lowest ASDR Africa Western Pacific, respectively. annual incidence hepatocellular carcinoma (HCC) among patients ranged 0.9% 5.6%. Alcohol approximately one-fifth HCC-related 2019. Between 2012 2017, for declined, but liver cancer increased. Measures are required curb heavy reduce burden HCC. Degree intake, sex, older age, obesity, type 2 diabetes mellitus, gut microbial dysbiosis genetic variants key factors development this Review, we discuss epidemiology, projections risk

Language: Английский

Citations

277
Combination immunotherapy for hepatocellular carcinoma DOI Open Access
Lorenza Rimassa, Richard S. Finn, Bruno Sangro

et al.

Journal of Hepatology, Journal Year: 2023, Volume and Issue: 79(2), P. 506 - 515

Published: March 16, 2023

Language: Английский

Citations

169
Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity DOI Creative Commons
Hsuan-An Chen, Yu-Jui Ho, Riccardo Mezzadra

et al.

Cancer Discovery, Journal Year: 2022, Volume and Issue: 13(2), P. 432 - 453

Published: Oct. 27, 2022

Abstract Cellular senescence involves a stable cell-cycle arrest coupled to secretory program that, in some instances, stimulates the immune clearance of senescent cells. Using an immune-competent liver cancer model which triggers CD8 T cell–mediated tumor rejection, we show that also remodels cell-surface proteome alter how cells sense environmental factors, as exemplified by type II interferon (IFNγ). Compared with proliferating cells, upregulate IFNγ receptor, become hypersensitized microenvironmental IFNγ, and more robustly induce antigen-presenting machinery—effects recapitulated human undergoing therapy-induced senescence. Disruption sensing blunts their immune-mediated without disabling state or its characteristic program. Our results demonstrate have enhanced ability both send receive signals imply each process is required for effective surveillance. Significance: work uncovers interplay between tissue remodeling tissue-sensing programs can be engaged advanced cancers render visible adaptive system. This new facet establishes reciprocal heterotypic signaling interactions induced therapeutically enhance antitumor immunity. See interview Direna Alonso-Curbelo, PhD, recipient inaugural Cancer Discovery Early Career Award: https://vimeo.com/992987447 related article Marin et al., p. 410. highlighted In Issue feature, 247

Language: Английский

Citations

127
Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects DOI Creative Commons

Zhuoyan Liu,

Xuan Liu, Jiaxin Liang

et al.

Frontiers in Immunology, Journal Year: 2021, Volume and Issue: 12

Published: Oct. 4, 2021

Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer with poor prognosis. Surgery, chemotherapy, and radiofrequency ablation are three conventional therapeutic options that will help only a limited percentage of HCC patients. Cancer immunotherapy has achieved dramatic advances in recent years provides new opportunities to treat HCC. However, various etiologies can evade immune system through multiple mechanisms. With rapid development genetic engineering synthetic biology, variety novel immunotherapies have been employed advanced HCC, including checkpoint inhibitors, adoptive cell therapy, engineered cytokines, vaccines. In this review, we summarize current landscape research progress different strategies treatment The challenges field also discussed.

Language: Английский

Citations

114
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study DOI
Alessandro Rizzo, Veronica Mollica, Valentina Tateo

et al.

Cancer Immunology Immunotherapy, Journal Year: 2023, Volume and Issue: 72(6), P. 1381 - 1394

Published: Jan. 25, 2023

Language: Английский

Citations

112
Integrated Machine Learning and Bioinformatic Analyses Constructed a Novel Stemness-Related Classifier to Predict Prognosis and Immunotherapy Responses for Hepatocellular Carcinoma Patients DOI Creative Commons
Dongjie Chen, Jixing Liu,

Longjun Zang

et al.

International Journal of Biological Sciences, Journal Year: 2021, Volume and Issue: 18(1), P. 360 - 373

Published: Dec. 15, 2021

Immunotherapy has made great progress in hepatocellular carcinoma (HCC), yet there is still a lack of biomarkers for predicting response to it.Cancer stem cells (CSCs) are the primary cause tumorigenesis, metastasis, and multi-drug resistance HCC.This study aimed propose novel CSCs-related cluster HCC predict patients' immunotherapy.Based on RNA-seq datasets from The Cancer Genome Atlas (TCGA) Progenitor Cell Biology Consortium (PCBC), one-class logistic regression (OCLR) algorithm was applied compute stemness index (mRNAsi) patients.Unsupervised consensus clustering performed categorize patients into two subtypes which further proved be predictor tumor immune microenvironment (TIME) status, immunogenomic expressions sensitivity neoadjuvant therapies.Finally, four machine learning algorithms (LASSO, RF, SVM-RFE XGboost) were distinguish different subtypes.Thus, five-hub-gene based classifier constructed TCGA ICGC subtype more convenient applicable way, this stemness-based classification system could facilitate prognostic prediction guide clinical strategies immunotherapy targeted therapy HCC.

Language: Английский

Citations

104